Claire  Fraser net worth and biography

Claire Fraser Biography and Net Worth

Claire M. Fraser, Ph.D., serves as a director of BD (Becton, Dickinson and Company), a global medical technology company headquartered in Franklin Lakes, New Jersey. Dr. Fraser has been a member of the board since 2016.

Dr. Fraser is the director of the Institute for Genome Sciences and a Professor of Medicine and Microbiology and Immunology at the University of Maryland School of Medicine in Baltimore, Maryland. From 1998 to 2007, she served as president and director of The Institute for Genomic Research, a not-for-profit research organization engaged in human and microbial genomics studies. Dr. Fraser is the president and a director of the American Association for the Advancement of Science and also serves as a director of Ohana Biosciences Inc.

Dr. Fraser is a prominent scientist with a strong background in infectious diseases and molecular diagnostics, including the development of novel diagnostics and vaccines. She also brings considerable managerial experience in her field.

What is Claire Fraser's net worth?

The estimated net worth of Claire Fraser is at least $5.06 million as of August 28th, 2023. Dr. Fraser owns 21,608 shares of Becton, Dickinson and Company stock worth more than $5,063,403 as of July 24th. This net worth approximation does not reflect any other assets that Dr. Fraser may own. Learn More about Claire Fraser's net worth.

How do I contact Claire Fraser?

The corporate mailing address for Dr. Fraser and other Becton, Dickinson and Company executives is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. Becton, Dickinson and Company can also be reached via phone at (201) 847-6800 and via email at [email protected]. Learn More on Claire Fraser's contact information.

Has Claire Fraser been buying or selling shares of Becton, Dickinson and Company?

Claire Fraser has not been actively trading shares of Becton, Dickinson and Company within the last three months. Most recently, Claire Fraser sold 848 shares of the business's stock in a transaction on Monday, August 28th. The shares were sold at an average price of $281.66, for a transaction totalling $238,847.68. Following the completion of the sale, the director now directly owns 21,608 shares of the company's stock, valued at $6,086,109.28. Learn More on Claire Fraser's trading history.

Who are Becton, Dickinson and Company's active insiders?

Becton, Dickinson and Company's insider roster includes Simon Campion (EVP), Alexandre Conroy (EVP), Christopher DelOrefice (Exec. VP & CFO ), Claire Fraser (Director), John Gallagher (VP), Michael Garrison (EVP), Roland Goette (EVP), David Hickey (EVP), Patrick Kaltenbach (EVP), Samrat Khichi (EVP), Betty Larson (EVP), James Lim (EVP), Thomas Polen, Jr. (Insider), Rebecca Rimel (Director), and Thomas Spoerel (VP). Learn More on Becton, Dickinson and Company's active insiders.

Are insiders buying or selling shares of Becton, Dickinson and Company?

During the last year, insiders at the medical instruments supplier sold shares 10 times. They sold a total of 16,634 shares worth more than $4,166,149.15. The most recent insider tranaction occured on June, 10th when SVP Thomas J Spoerel sold 300 shares worth more than $71,793.00. Insiders at Becton, Dickinson and Company own 0.3% of the company. Learn More about insider trades at Becton, Dickinson and Company.

Information on this page was last updated on 6/10/2024.

Claire Fraser Insider Trading History at Becton, Dickinson and Company

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/28/2023Sell848$281.66$238,847.6821,608View SEC Filing Icon  
2/8/2022Sell841$271.70$228,499.70View SEC Filing Icon  
8/18/2021Sell387$251.58$97,361.46View SEC Filing Icon  
5/27/2021Sell390$241.36$94,130.40View SEC Filing Icon  
2/11/2020Sell1,500$258.72$388,080.00View SEC Filing Icon  
8/7/2019Sell1,429$243.26$347,618.54View SEC Filing Icon  
See Full Table

Claire Fraser Buying and Selling Activity at Becton, Dickinson and Company

This chart shows Claire Fraser's buying and selling at Becton, Dickinson and Company by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Becton, Dickinson and Company Company Overview

Becton, Dickinson and Company logo
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Read More

Today's Range

Now: $236.08
Low: $234.46
High: $237.00

50 Day Range

MA: $232.29
Low: $221.47
High: $240.63

2 Week Range

Now: $236.08
Low: $218.75
High: $286.46

Volume

242,219 shs

Average Volume

1,418,116 shs

Market Capitalization

$68.23 billion

P/E Ratio

52.00

Dividend Yield

1.64%

Beta

0.42